SLC5A2 and diabetes mellitus: <i>Results:</i> A significant "confounding by indication" was observed; the SGLT2 group presented a high-risk phenotype with higher diabetes prevalence (56.3% vs. 25.7%, <i>p</i> < 0.001), lower baseline LVEF (38.3% vs. 43.3%), and greater hypertrophy.